Ali S Taha1,2, Claire Kelly2, Caroline McCloskey1, Theresa Craigen1, Wilson J Angerson3. 1. Department of Gastroenterology, University Hospital Crosshouse, Kilmarnock, Scotland, UK. 2. Department of Medicine, University of Glasgow, Kilmarnock, Scotland, UK. 3. The University Department of Surgery, University of Glasgow, Glasgow, Scotland, UK.
Abstract
OBJECTIVES: In recent years, policies have been proposed in order to guide the safer use of non-steroidal anti-inflammatory drugs (NSAIDs) and antiulcer therapy. We aimed to investigate the incidence of upper gastrointestinal bleeding (UGIB) before and after the introduction of these policies, 2007-2009, in a well-defined population in southwest Scotland. METHODS: All patients with non-variceal upper gastrointestinal bleeding (NV-UGIB), diagnosed at a single regional unit, were included. Total drugs prescribed in our population were noted, including antiulcer drugs, antithrombotic drugs and both cyclo-oxygenase-2 enzyme-selective and non-selective inhibiting NSAIDs. RESULTS: The incidence, the number of cases per 100 000 population per annum, of NV-UGIB fell from 134.7 in 2007 to 125.1 in 2008, and to 90.3 cases in 2009 (p<0.001). There was also a significant rise in the use of non-selective NSAIDs, proton pump inhibitors and antithrombotic drugs. CONCLUSIONS: Although a cause-and-effect relationship cannot be fully proven, physician education through drug-use policies is associated with a drop in the incidence of NV-UGIB. This is relevant to the prevention of this common condition.
OBJECTIVES: In recent years, policies have been proposed in order to guide the safer use of non-steroidal anti-inflammatory drugs (NSAIDs) and antiulcer therapy. We aimed to investigate the incidence of upper gastrointestinal bleeding (UGIB) before and after the introduction of these policies, 2007-2009, in a well-defined population in southwest Scotland. METHODS: All patients with non-variceal upper gastrointestinal bleeding (NV-UGIB), diagnosed at a single regional unit, were included. Total drugs prescribed in our population were noted, including antiulcer drugs, antithrombotic drugs and both cyclo-oxygenase-2 enzyme-selective and non-selective inhibiting NSAIDs. RESULTS: The incidence, the number of cases per 100 000 population per annum, of NV-UGIB fell from 134.7 in 2007 to 125.1 in 2008, and to 90.3 cases in 2009 (p<0.001). There was also a significant rise in the use of non-selective NSAIDs, proton pump inhibitors and antithrombotic drugs. CONCLUSIONS: Although a cause-and-effect relationship cannot be fully proven, physician education through drug-use policies is associated with a drop in the incidence of NV-UGIB. This is relevant to the prevention of this common condition.
Authors: C Mel Wilcox; Jeroan Allison; Keith Benzuly; Marie Borum; Byron Cryer; Tilo Grosser; Richard Hunt; Uri Ladabaum; Angel Lanas; Harold Paulus; Carol Regueiro; Robert S Sandler; Lee Simon Journal: Clin Gastroenterol Hepatol Date: 2006-07-31 Impact factor: 11.382
Authors: A Lanas; L A García-Rodríguez; M Polo-Tomás; M Ponce; E Quintero; M A Perez-Aisa; J P Gisbert; L Bujanda; M Castro; M Muñoz; M D Del-Pino; S Garcia; X Calvet Journal: Aliment Pharmacol Ther Date: 2011-01-05 Impact factor: 8.171
Authors: Ali S Taha; Caroline McCloskey; Theresa Craigen; Wilson J Angerson; Amir A Shah; Christopher G Morran Journal: Frontline Gastroenterol Date: 2011-07-16
Authors: A S Taha; N Hudson; C J Hawkey; A J Swannell; P N Trye; J Cottrell; S G Mann; T J Simon; R D Sturrock; R I Russell Journal: N Engl J Med Date: 1996-05-30 Impact factor: 91.245
Authors: Chuan-Guo Guo; Feifei Zhang; Joseph T Wu; Ka-Shing Cheung; Bofei Li; Simon Y K Law; Wai K Leung Journal: United European Gastroenterol J Date: 2021-05-06 Impact factor: 4.623